Psyence Biomedical (PBM) Total Non-Current Liabilities (2024 - 2025)
Psyence Biomedical's (PBM) quarterly Total Non-Current Liabilities came in at $644700.0 in Q3 2025, down 80.81% year-on-year from $3.4 million in Q3 2024, and up 63.52% quarter-over-quarter from $394270.0 in Q1 2025.
Psyence Biomedical (PBM) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Psyence Biomedical's Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $644700.0 for Q3 2025.
- On a quarterly basis, Total Non-Current Liabilities fell 80.81% year-over-year to $644700.0 in Q3 2025; TTM through Sep 2025 was $644700.0, a 80.81% decrease from a year earlier, with the FY2025 full-year figure at $394270.0, down 96.48% from the prior year.
- Total Non-Current Liabilities grew to $644700.0 in Q3 2025 per PBM's latest filing, from $394270.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $11.2 million in Q1 2024 and bottomed at $394270.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Psyence Biomedical | 1.56 Mn | 1.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 644,700.00 |
| Mar 31, 2025 | 394,270.00 |
| Sep 30, 2024 | 3.36 Mn |
| Mar 31, 2024 | 11.20 Mn |